Profile: Sagent Pharmaceuticals Inc (SGNT.OQ)
21.26USD
1:02pm EDT
$-0.42 (-1.94%)
$21.68
$21.74
$21.74
$20.88
7,412
37,501
$23.25
$12.66
Sagent Pharmaceuticals, Inc. (Sagent), incorporated in 2006, is an injectable pharmaceutical company, which develops and sources products, which the Company sells in the United States. The Company offers its customers a range of products across anti-infective, oncolytic and critical care indications in a range of presentations, including single- and multi-dose vials, pre-filled ready-to-use syringes, medical devices and premix bags, and it focuses to develop injectable products. As of December 31, 2010, it marketed 22 products, all of which were generic injectable products, and had a pipeline, which included 46 new products represented by 77 Abbreviated New Drug Applications (ANDAs), which either are under review by the United States Food and Drug Administration (FDA) or were approved and their associated products are pending commercial launch.
The Company’s products feature its PreventIV Measures packaging and labeling. PreventIV Measures is its approach to packaging and labelling. Its PreventIV Measures approach incorporates label and carton designs, cap and label colors, bar coding, latex-free packaging components and other features. Its products can be classified into the three product categories: anti-infective, oncology and critical care. Its anti-infective products assist in the treatment of various infections and related symptoms, its oncology products are used in the treatment of cancer and cancer-related medical problems and its critical care products are used in a range of critical care applications and include anesthetics, cardiac medications, steroidal products and sedatives. During the year ended December 31, 2010, within its anti-infective product category, cefepime accounted for approximately 26% of its net revenues. During 2010, within its critical care product category, its heparin products accounted for approximately 26% of its net revenues.
Anti-Infective Products
Cefepime is a fourth-generation cephalosporin, an antibiotic used to treat a range of infections, including infections of the urinary tract, skin and skin structure, as well as moderate to severe pneumonia, complicated intra-abdominal infections, and as empiric therapy for febrile neutropenic patients. iprofloxacin is a synthetic antimicrobial agent used to treat a range of infections, including infections of the urinary tract, skin and skin structure, bones and joints, as well as nosocomial pneumonia, acute sinusitis, chronic bacterial prostatitis, lower respiratory infections and complicated intra-abdominal infections. Ciprofloxacin belongs to the fluoroquinolone family of drugs.
Oncology Products
Epirubicin hydrochloride is indicated as a component of adjuvant therapy in patients with evidence of axillary node tumor involvement resection of breast cancer. Epirubicin hydrochloride is the generic equivalent to Pfizer’s Ellence. Fludarabine phosphate is indicated for the treatment of adult patients with B-cell chronic lymphocytic leukemia who have not responded to or whose disease has progressed during treatment with at least one standard alkylating agent containing regimen. Topotecan hydrochloride is a topoisomerase inhibitor indicated for cell lung cancer sensitive disease after failure of first-line chemotherapy and combination therapy with cisplatin for stage IV-B, recurrent, or persistent carcinoma of the cervix, which is not amenable to curative treatment with surgery and/or radiation therapy.
Critical Care Products
Adenosine is an antiarrhythmic commonly used in the treatment of cardiac rhythm disturbances in critical care situations. Heparin is an anticoagulant used to prevent and treat blood clotting, especially during and after surgery and dialysis. In July 2010, it launched its heparin products in the United States. In July 2010, it launched nine different presentations of heparin sodium injection in latex-free vials following FDA’s approval of its three heparin ANDAs.
Product Pipeline and Development Program
The Company maintains an active product development program. Its product pipeline can be classified into two categories: new products, for which it has submitted or acquired ANDAs that are filed and under review by the FDA; and new products for which it has begun initial development activities, such as sourcing of active pharmaceutical ingredient (API) and finished products and preparing the necessary ANDAs. As of December 31, 2010, its new product pipeline included: 38 products represented by 68 ANDAs that it had filed, or licensed rights to, and were under review by the FDA, and eight products represented by nine ANDAs, which has been approved and are pending commercial launch, and approximately 51 additional products under initial development. As of December 31, 2010, its 68 ANDAs under review by the FDA had been on file for an average of approximately 21 months, with 19 of them being on file for less than 12 months, 23 of them being on file for between 12 and 24 months and 26 of them being on file for longer than 24 months.
The Company’s product development activities also include expanding its product portfolio by adding products through in-licensing and similar arrangements with foreign manufacturers and domestic virtual pharmaceutical development companies. As of December 31, 2010, it marketed 17 of its 22 products under these type of in-licensing arrangements. It either owns or licenses the rights to ANDAs for the products, which it markets and sells, which is determined based on the scope of services provided to it by a particular business partner.
The Company competes with Baxter International Inc., Boehringer Ingelheim Group , Fresenius SE, Hikma Pharmaceuticals PLC , Hospira, Inc., Pfizer Inc., Novartis AG and Teva Pharmaceutical Industries Ltd.
Company Address
Sagent Pharmaceuticals Inc
STE 700, 1901 N ROSELLE RD
SCHAUMBURG IL 60195
P: +1847.9081600
F: +1847.9081601
Company Web Links
| Name | Compensation |
|---|---|
Jeffrey Yordon |
6,118,340 |
James Hussey |
-- |
Jonathon Singer |
778,685 |
Michael Logerfo |
355,575 |
Albert Patterson |
354,368 |

